Tag: Rollout

Categories
Business

5G rollout boosts demand for backup energy technology, Generac CEO says

5G rollout boosts demand for backup power generation, Generac CEO says

Aaron Jagdfeld, CEO of Generac, told CNBC on Monday that the emergency generator company expects to benefit from the adoption of 5G wireless technology.

“We believe this is an area that will grow tremendously over the next five years,” he said in an interview with Jim Cramer about Mad Money.

For Generac, the opportunity lies particularly in the telecommunications sector. The company is already a leading provider of backup generation for large wireless carriers, said Jagdfeld.

The introduction of 5G technology or the fifth generation cellular network promises faster network speeds and connecting more activities to the Internet of Things. The way people learn, drive and take care of their health is expected to be influenced by new technologies.

Because the networks are becoming even more critical for society, the demand for electricity security will only increase, according to Jagdfeld.

“None of this works without a continuous source of power, and telecommunications companies really need to improve their game on reliability, and that’s where we come in,” he said.

Generac’s shares fell more than 2% on Monday, trading at $ 293.95. The stock is up nearly 30% since the start of the year.

Categories
Health

Prime Biden Covid officers to debate vaccine rollout with Home after J&J pictures paused

Top Biden Covid officials to discuss vaccine rollout with House after J&J shots paused

Dr. Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases (left), speaks to Dr. David Kessler, Chief Science Officer of the White House COVID-19 Response Team on the Federal Coronavirus Response on Capitol Hill March 18, 2021 in Washington, DC.

Susan Walsh | Getty Images

The House’s coronavirus subcommittee will hear from three leading health officials in the Biden government on Thursday about United States efforts to step up vaccinations as Covid cases, including those of dangerous variants, are on the rise.

The hearing, which will also focus on the continued need for people to wear masks and follow social distancing measures, is slated to begin at 10:30 a.m. ET. It is streamed live.

The event comes two days after dozens of states abruptly stopped administering Johnson & Johnson’s single-dose Covid vaccine in response to the Food and Drug Administration’s recommendation to suspend those recordings while investigating cases of women, who have developed a rare bleeding disorder.

Some fear the recommendation, issued in response to six reported blood clot cases from nearly 7 million J&J doses administered, could hamper the global campaign to vaccinate the world against the pandemic.

The selected subcommittee on the coronavirus crisis, led by James Clyburn, DS.C., is led by Dr. Anthony Fauci, the country’s foremost infectious disease expert, and the director of the Center for Disease Control and Prevention Dr. Rochelle Walensky. David Kessler, a senior Covid official in President Joe Biden’s Department of Health and Human Services, is also on the witness list.

Dr. Rochelle Walensky, director of Centers for Disease Control and Prevention, listens to the response from Covid-19, DC during a hearing with the Senate Committee on Health, Education, Labor and Pensions on March 18, 2021 in Washington on Capitol Hill, DC .

Anna Moneymaker | Getty Images

While the US is vaccinating more people than ever before, Covid cases are increasing in more than half of its states. According to the Johns Hopkins University, an average of more than 71,000 cases per day were counted for the past week.

“It’s almost a race between vaccinating people and this surge that is apparently about to increase,” Fauci told CNN on Wednesday.

The emergence of variants of Covid – like B 1.1.7, which recently flooded Michigan and is now the most common strain in the US – has led health officials to urge Americans to continue to take precautionary measures despite accelerated vaccination efforts.

Experts say Johnson & Johnson’s recent vaccination problems could fuel skepticism about vaccines.

In their quest to have all eligible individuals in the U.S. vaccinated against Covid, officials have stressed that all of the options available – from Pfizer-BioNTech, Moderna, and Johnson & Johnson – are safe and effective. All three have been approved by the FDA for emergency use. Pfizer and Moderna vaccines require two separate doses given three to four weeks apart.

But the six cases of women who developed the rare blood clots urged the FDA to stop J & J’s shot “out of caution.”

All women developed the disease within about two weeks of being vaccinated, health officials told reporters Tuesday. One of the women died.

“I think it will affect the hesitation, period. Whether it should or not is a different matter,” said Dr. Jeffrey Kahn, director of the Berman Institute of Bioethics at Johns Hopkins University, told CNBC.

With Johnson & Johnson’s vaccine only containing one dose, experts say the hiatus could also reduce vaccine access for some communities.

“This vaccine was biased to be used in harsher environments, places where you couldn’t deliver two doses. You wanted to deliver one dose and stick to the vaccination schedule,” said Dr. Scott Gottlieb, who sits on the Pfizer board of directors at CNBC on Tuesday.

– The Associated Press contributed to this report.

Disclosure: Scott Gottlieb is a CNBC employee and a member of the boards of directors of Pfizer, genetic testing startup Tempus, health technology company Aetion Inc., and biotech company Illumina. He is also co-chair of Norwegian Cruise Line Holdings and Royal Caribbean’s Healthy Sail Panel.

Categories
World News

Chile’s coronavirus circumstances hit document ranges regardless of vaccine rollout

Chile's coronavirus cases hit record levels despite vaccine rollout

A health worker administers a dose of the Pfizer BioNTech vaccine against Covid-19 to a man at Medalla Milagrosa Church in Valparaiso, Chile, on April 6, 2021.

JAVIER TORRES | AFP | Getty Images

LONDON – Chile’s vaccination campaign against the coronavirus has been one of the fastest and most extensive in the world, but a recent surge in infections has raised concern beyond its borders.

Almost 40% of the total population of the South American country have received at least one dose of a Covid-19 vaccine, according to statistics from Our World in Data, reflecting one of the highest vaccination rates in the world.

Only Israel and the UK have vaccinated a greater proportion of their population with at least one dose.

Nonetheless, Chile has seen a sharp increase in coronavirus infections in recent weeks, despite the world-famous vaccine rollout and strict bans affecting a large part of its 19 million residents.

The regional director of the Pan American Health Organization has since emphasized that for most countries in the region, vaccines are insufficient to prevent rising infection rates.

The number of daily cases in Chile rose to a record high on April 9, rising to over 9,000 for the first time since the pandemic began and well above the high of nearly 7,000 last summer.

Health Minister Enrique Paris told reporters on Thursday that he hoped the increase in daily cases has now peaked.

“Once we hit that peak, we don’t expect a decrease, but rather a stabilization and then a return to a smaller number of positive patients,” he said, according to Reuters.

What went wrong?

Health experts say the country’s recent surge in cases is partly due to more virulent strains of the virus, easing public health measures, increased mobility, and defiance of simple precautions like physical distancing and wearing a mask.

The center-right government of Chile, led by President Sebastian Pinera, ordered the country’s borders to be closed from March to November 2020, albeit with a few exceptions, before it was decided at the end of last year to reopen them to international passengers.

Shops, restaurants and some resorts have also opened to help boost the country’s pandemic-hit economy.

Passengers in protective suits against the spread of the novel coronavirus disease are queuing at the counters of Arturo Merino Benitez International Airport in Santiago on April 1, 2021, after Chile announced that it would close its borders in April as COVID-19 rose sharply is cases.

MARTIN BERNETTI | AFP | Getty Images

While the country’s vaccination rollout was ahead of most, the spread of a more virulent strain of the virus – like the P.1 variant first spotted in travelers from Brazil – has resulted in a significant spike in cases.

Given the widespread use of CoronaVac, the coronavirus vaccine manufactured by Chinese company Sinovac, questions about the vaccine’s effectiveness have also been raised.

After the head of the China Center for Disease Control and Prevention stated earlier this month that China may need to replace its Covid vaccines or change the way they are administered to make them sufficiently effective.

“We will solve the problem that current vaccines do not have very high protection rates,” said George Gao, director general of China’s CDC, at a conference on April 11th. He has since told the state media that his comments have been misunderstood.

Late-stage data from China’s Covid vaccines remain unpublished, and the data available from the CoronaVac vaccine varies. Brazilian studies found the vaccine to be just over 50% effective and significantly less effective than Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca, while Turkish researchers reported 83.5% effectiveness.

An ambulance leaves Carlos Van Buren Hospital in Valparaiso, Chile on April 6, 2021, overwhelmed by the large number of Covid-19 positive cases.

JAVIER TORRES | AFP | Getty Images

A study published earlier this month by the University of Chile reported that CoronaVac was 56.5% effective in the country two weeks after giving the second doses. It was also crucial, however, that a dose was only 3% effective.

“This would explain why Chile – with one of the most robust vaccine launches in the world, but 93% of the doses sourced from China – has seen a significant spike in cases and a much slower decline in hospital admissions and deaths compared to the early rollouts in.” Israel, UK and US, “said Ian Bremmer, President of Eurasia Group’s Risk Advisory Group, in a research note.

“Chile and the United Arab Emirates are both considering introducing a third dose (a second booster) of the Chinese vaccine accordingly. A change in communication will make the vaccine more hesitant for Chinese vaccines in general,” said Bremmer.

“Comprehensive Strategies”

“I cannot stress this enough – for most countries, vaccines are not going to stop this wave of the pandemic,” PAHO director Carissa Etienne said during a weekly press conference Wednesday. “There just isn’t enough of it to protect everyone in the most at-risk countries.”

Etienne urged policymakers in the region to implement “comprehensive strategies” to accelerate vaccine adoption and stop transmission through best public health measures.

On April 14, America reported more than 1.3 million Covid infections and nearly 36,000 deaths in the past week, according to the United Nations Health Department.

To date, America has recorded 58.8 million cases and more than 1.4 million deaths, making it the worst-hit region in the world.

“We are not acting like a region in the middle of a worsening outbreak,” said Etienne of PAHO, describing South America as the “epicenter” of the virus.

In addition to easing restrictions in some areas, Etienne said that new and highly communicable variants of the virus had accelerated cases sharply. Currently, Brazil, Colombia, Venezuela, Peru and some areas of Bolivia are seeing a sharp increase in infections.

Paraguay, Uruguay, Argentina and Chile are also seeing sustained increases in Covid cases, Etienne said.

Categories
Health

Sluggish rollout offers lesson in EU politics

Slow rollout gives lesson in EU politics

Ursula von der Leyen, European Commission president.

Bloomberg | Bloomberg | Getty Images

LONDON – European Commission President Ursula von der Leyen said it herself: “It was a difficult start.”

The European Union has had a bumpy introduction of Covid-19 vaccines. The campaign has sparked complaints that regulators were too slow to approve the shots and sparked a simmering argument with AstraZeneca as the pharmaceutical company repeatedly cut its delivery obligations.

More recently, several countries have temporarily stopped using the Oxford-AstraZeneca vaccine for safety reasons. This has baffled health professionals and raised questions about future intake.

The World Health Organization earlier this week expressed concern that the ongoing coronavirus crisis in the region now appears “more worrying” than it has for several months. The warning comes as many countries introduce new measures to contain a third wave of infections.

The health department also described the vaccination campaign in Europe as “unacceptably slow” and said it was crucial to accelerate the rollout, as new infections are currently emerging in every age group except those over 80 years of age.

It is a chaotic picture, made even more complicated by the uniqueness of European politics.

“There were several problems with the system, and it is a complex system. I think it is important not to point the finger at a certain defect, but to realize that it is very complex,” said Linda Bauld, professor for public health at the University of Edinburgh, said CNBC.

The European Commission, the EU’s executive branch, was responsible for negotiating contracts with pharmaceutical companies on behalf of the 27 member states. The institution is also responsible for overseeing the exports of the shots produced in the block.

However, health policy matters are the responsibility of the Member States, which means that the 27 capitals can organize the vaccinations in their own countries and ultimately decide to buy Covid shots, for example outside of the agreements made by the Commission.

This juxtaposition between national and EU institutions has often damaged the bloc’s reputation in broader vaccination efforts.

“There are problems that have to do with both (national and EU institutions). There is clearly politics in it and we have all heard about it in the media, but there are also problems with decision-making and attitudes the commissions have to do and the priorities of the member states, “Bauld told CNBC.

AstraZeneca weft suspension

This was highlighted recently when 13 EU countries decided to stop using the Oxford AstraZeneca shot while investigating possible side effects.

At the time, the European Medicines Agency – the medicines agency for the entire 27-member region – was recommending countries to continue using the vaccine, despite reviewing data on blood clots in some vaccinated people. However, some member states preferred to be cautious and used their sovereign power to stop the use of this vaccine as the EMA completed its review. The Safety Committee of the Medicines Agency concluded in a preliminary review that the benefits of the vaccine continue to outweigh the risk of side effects.

It has also been the case that heads of state have used the institutions in Brussels to complain about the hiccups in the process. At the beginning of March, the Austrian Chancellor Sebastian Kurz said the decision to distribute the vaccines in the Commission’s steering committee was “secret”.

The group, chaired by the Commission, has representatives from all Member States, including Austria.

“Why do you get this idea when you know that Austria, like the 26 other member states, is a member of the steering committee and how the others have been informed about the previous allocations?” An EU official from another Member State who did not want to be named due to the sensitivity of the issue asked during a CNBC interview in March.

The vaccines are distributed proportionally depending on the population of the countries. However, some EU states were particularly interested in getting more of the AstraZeneca shot, as it’s cheaper and easier to store than the Pfizer BioNTech vaccine.

“If a Member State decides not to start its pro-rata allocation, the doses will be shared among the other interested Member States,” the Commission said in a statement in March.

We also know that AstraZeneca has unfortunately produced too little and delivered too little. And this, of course, painfully reduced the speed of the vaccination campaign.

Ursula von der Leyen

President of the European Commission

Vaccine distribution has become an issue due to AstraZeneca’s repeated cuts in supplies.

While the EU was expecting 90 million doses of the shot by the end of the first quarter, the pharmaceutical company said it could only deliver 40 million doses during that period. This was later reduced to 30 million cans.

AstraZeneca has blamed low yields at European plants for lower shipments. In addition, the drug maker has said it can only administer 70 million doses between April and June when the EU was expecting 180 million over the same period.

“We also know that AstraZeneca has unfortunately produced too little and delivered too little. And of course this has painfully reduced the speed of the vaccination campaign,” said von der Leyen at a press conference in March.

Stricter export rules

To address this problem, the Commission proposed stricter rules for the export of ingot-made shots.

Since the end of January, the 27 countries have been able to stop delivering Covid vaccines if a company does not meet delivery targets with the EU. This is how the Italian government stopped a delivery of AstraZeneca shots to Australia in March. Between the end of January and the end of March, the Commission received 315 applications for vaccine exports, but only this one was rejected.

However, as EU officials are concerned about further delivery delays, the Commission decided to tighten export regulations from the end of March.

I think the EU definitely prioritizes its population first, but it is no different from other high-income countries or regions.

Dimitri Eynikel

Coordinator at Medecins sans Frontieres

The Commission will not only check whether the pharmaceutical companies deliver on time, but also whether the recipient country has bans or restrictions on Covid vaccines produced there and whether this country also has a better epidemiological situation than the EU.

“At the political level, the entire discussion about export restrictions, controls or even bans is rather worrying,” Dimitri Eynikel, coordinator at Medecins sans Frontieres, told CNBC. He added that doing so could create further barriers, divisions and delays in vaccine distribution.

Ultimately, the supply chain is international and if a nation stopped sending raw materials to the EU, for example, it could undermine the production of the shots within the bloc.

The EU’s attempt to have tighter control over where vaccines go has sparked criticism of vaccine nationalism.

“I think the EU definitely prioritizes its people first, but it is no different from any other high-income country or region. The US is doing the same thing, the UK is doing the same thing, in that sense (the EU) is no different.” Said Eynicle.

International Monetary Fund data has shown that China, India and the EU are among the largest exporters of Covid shots, while the US and UK have not exported any to date.

Hopes for the second quarter

Despite several problems, the EU is confident that the next three months will prove to be a turning point in the vaccination program.

In total, the commission expects 360 million doses of Covid shots between April and June, meaning it is well positioned to meet its goal of vaccinating 70% of the adult population before the end of summer.

“Despite the fact that things could have gone faster, we had great success. The alternative of not having vaccines sourced together would be that we would compete between European member states and possibly some of us did not.” Vaccine at this point too, “Malta’s Minister of Health Chris Fearne told CNBC’s Squawk Box Europe on Tuesday.

Categories
Business

UK provides to gradual in coming weeks, rollout in danger

UK regulator warns those with history of significant allergic reactions

Assistant Nurse Katie McIntosh gives Vivien McKay, Clinical Nurse Manager at Western General Hospital, the first of two Pfizer / BioNTech COVID-19 shots on the first day of the largest vaccination program in UK history in Edinburgh, Scotland, UK December 8 2020.

Andrew Milligan | Reuters

LONDON – The UK government is facing questions whether the country is on the verge of a coronavirus vaccine shortage, a factor that could affect its so far successful vaccination program.

“We have less supply than we had hoped for in the coming weeks, but we assume that it will increase again later,” said housing secretary Robert Jenrick on Thursday to the BBC.

“The vaccine rollout will be a little slower than we hoped it would be, but not slower than the target,” he said. “We have every reason to believe that supply will increase in May, June and July.”

Jenrick later told Sky News that the government “sources vaccines from all over the world and we occasionally have some problems and that has led to this problem with some supply in the coming weeks.”

Jenrick’s comments come amid a spate of reports in the UK media that the UK rollout may be close to some turmoil. It has been widely reported that a shipment of millions of cans of the Oxford AstraZeneca shot produced by the Serum Institute of India could be delayed by four weeks.

Jenrick, however, refused to comment on certain contracts. CNBC has approached the Serum Institute of India, the world’s largest vaccine maker, for comment on the reports but has yet to receive a response.

According to Reuters, ten million doses of the AstraZeneca Covid vaccine should come from the SII in early March. In total, the UK has ordered 100 million doses of the AstraZeneca-Oxford vaccine, with the bulk of the supply coming from the UK

However, the UK also faces potential disruptions in supply if the EU makes a proposal to withhold exports of block-made vaccines while its own program is lagging behind. The supplies of the Pfizer BioNTech vaccine, which the UK also uses in its vaccination program, come from Belgium.

Since its launch in December, the UK healthcare system has monitored the vaccination of over 25 million people with a first dose of the vaccine. More than 1.7 million people have now received a second dose of the two-shot vaccines currently used in the UK, government data shows.

“Still on the right track”

According to the BBC, the National Health Service had already warned “in April in a letter to the local health organizations” against a reduction in the offer for England.

However, the government has stated that it is still on track to offer a first dose of the vaccine to all over 50s by April 15 and a first vaccination to all UK adults by the end of July.

“The vaccination program will continue in the coming weeks and more people will continue to receive the first and second dose,” a spokesman for the Ministry of Health and Social Affairs said in a statement on Wednesday evening.

“As has been the case since the program began, the number of vaccinations given over time will vary based on supply.”

‘Main problem’

Global health experts have long warned that vaccines, their supply and distribution could be an area where there could be discord between countries and regions.

Dr. Margaret Harris, a spokeswoman for the World Health Organization, told CNBC Thursday that the public health authority knew from the start of the pandemic that vaccine distribution would be a “big problem”.

“This is exactly what has happened in previous outbreaks. Some groups and countries had good access (to vaccines) and even excessive access, while many countries had nothing. We saw this during the 2009 pandemic flu,” she told CNBC’s Squawk Box Europe “.

“We’re really encouraging manufacturers to take steps so that more manufacturing companies around the world can really increase supply,” she said.

The UK vaccination program was his rescue after the pandemic that hit the country hard. The UK has had the fifth highest number of cases in the world, with over 4.2 million reported infections, and has recorded over 126,000 deaths to date, according to Johns Hopkins University.

Categories
Health

Coronavirus anniversary: Europe’s gradual vaccine rollout

Coronavirus anniversary: Europe's slow vaccine rollout

On Tuesday, January 12, 2021, a health care worker will take care of a Covid 19 patient in the intensive care unit of the Robert Bosch Hospital in Stuttgart. Chancellor Angela Merkel warned that Germany would face tough lockdown measures until the end of March if the authorities do not contain a rapidly spreading variant of the coronavirus.

Bloomberg | Bloomberg | Getty Images

It’s been a year since the World Health Organization declared the coronavirus outbreak a pandemic, and as the UK and US progress with their vaccination rollouts, the EU is still in the depths of crisis.

The block is currently in a lethargic vaccination program and there are fears of another wave of infections from Paris to Prague.

On the first anniversary of the public health crisis, Europe doesn’t have much time to ponder the losses of the past year – when over 547,000 people in the region died from the virus and thousands lost their livelihoods.

There are more and more cases in parts of the bloc, mainly caused by the spread of more infectious virus variants, from western EU country France to Central Europe to Hungary in the east.

France reported 30,303 new coronavirus infections in the past 24 hours on Wednesday, with the number of new cases rising above 30,000 for the first time in two weeks. Health experts say the hospital system in the greater Paris area is on the verge of rupture, Reuters reported.

Meanwhile, Hungary, the Czech Republic and Poland have seen large increases in cases, which has led Eastern European governments to increase vaccination rates. So much so that several countries have resorted to a break with the EU with the approval of the Russian coronavirus vaccine Sputnik V, which has not yet been approved by the EU drug regulator.

Bulgaria and Serbia, as well as Sweden and Italy, are also among the countries where there has been an increase in cases.

The coronavirus, which first appeared in Wuhan in December 2019, was declared a pandemic a year ago, on March 11, 2020.

At this point it had already formed in northern Italy, which became the epicenter of Europe’s first eruption. The timing of the spread coincided with the peak of the ski season, allowing the virus to spread to the UK, France and Germany.

The EU’s Covid Experience

National responses to the pandemic have varied, but the EU tried to coordinate its response, closing external borders for all but non-essential travel, and coordinating purchases of personal protective equipment and medical supplies such as ventilators.

However, the state and structure of health services in different parts of the EU, as well as the tracking and tracing systems in place, played a role in determining the spread and damage caused by the virus.

Germany, for example, has been praised for its initial response to the virus, in which the infected and their contacts were tracked down and isolated. Modern hospital infrastructure has also helped limit the number of deaths compared to other countries. Germany (with around 83 million inhabitants) has so far reported 2.5 million cases and 72,858 deaths compared to Italy (a country of 60.3 million people), 3.1 million cases and 100,811 deaths, according to data from Johns Hopkins University.

In total, according to the European Center for Disease Control and Prevention in the EU and in the entire European Economic Area (essentially in the EU plus Iceland, Liechtenstein and Norway), over 22.5 million cases have been reported so far.

The extent to which countries blocked their economies and public life during the pandemic also had an impact on infection rates.

Most of the countries in the EU chose to close all shops but the main ones, to close gyms, restaurants, theaters and bars, and to close the region’s cultural and social life and economy. Although some, like Sweden, were notable for their decision not to lock, they sparked controversy and criticism from other EU countries, especially their neighbors.

However, it has gradually moved away from that position, especially in the face of a third wave of infections, and stricter restrictions on shops, gyms, swimming pools and sports facilities went into effect on March 6.

Economic damage

Economies across the bloc are hoping to open up as soon as possible, but the emergence of new, more virulent strains of the virus has ruined Christmas, ski season, and hopes that life could return to normal by Easter.

At the same time, vaccination adoption across the bloc remains painfully slow compared to the UK and US

The latest data from France shows that by March 9, 4.1 million people had received an initial coronavirus vaccine. In contrast, the UK had given over 22.8 million first doses at the same time.

The UK ordered, approved and administered vaccines faster than the EU, which placed orders in blocks rather than following individual guidelines. This was seen as an obstacle to the dynamics of the rollout.

The economic damage from the pandemic cannot be counted yet, but repeated lockdowns over the past year have taken their toll. A feared new wave could also delay a long-awaited reopening.

Data shows the damage the pandemic has already done to the region’s economy and citizens. Preliminary data from Eurostat, the EU data agency published in February, estimate that GDP (gross domestic product) fell by 6.8% in 2020 in the euro area and by 6.4% in the EU.

Eurostat estimates that 15.6 million men and women were unemployed in the EU in January 2021. Compared to January 2020, unemployment rose by 1.465 million in the EU and 1.010 million in the euro area.

Categories
Business

CVS and Walgreens have an opportunity to make Covid vaccine rollout extra equitable

Widespread Covid vaccines will be available in the spring, says Walgreens exec

Dr. Virginia Banks, eine Spezialistin für Infektionskrankheiten, gehört zu einer Gruppe schwarzer Ärzte und Wissenschaftler, die sich auf Möglichkeiten zur Lösung von Disparitäten im Gesundheitswesen konzentrieren.

Dr. Virginia Banks

Dr. Virginia Banks sagt, wenn die USA die Pandemie wirklich beenden wollen, werden sie mobile Transporter mit Impfstoffen in Gegenden nehmen, in denen die Menschen keinen Transport haben – und sogar in Friseursalons und Friseurläden schießen.

Da Tausende von Apotheken diese Woche Dosenlieferungen erhalten und Impfungen in ihren Läden beginnen, unternimmt das Land einen bedeutenden Schritt, um mehr Amerikaner zu erreichen. Beamte und Anwälte des öffentlichen Gesundheitswesens sagen jedoch, dass dies in Gemeinden, in denen die Menschen am kranksten waren, nicht weit genug gehen wird.

Weitere schwarze und hispanische Amerikaner wurden ins Krankenhaus eingeliefert und starben an Covid-19. Sie sind oft auch mit größeren Hindernissen konfrontiert, um Impfstoffe zu erhalten: Mangel an Transportmitteln. Ein Jonglieren mit mehreren Jobs. Zögern wegen Misshandlung durch die medizinische Gemeinschaft in der Vergangenheit.

CVS Health und Walgreens werden eine größere Rolle bei den Bemühungen spielen, da ein Bundesprogramm Dosen an mehr ihrer Geschäfte und die anderer Einzelhandelsapotheken versendet. Die Erweiterung stellt eine Geschäftsmöglichkeit für die beiden größten Apothekenketten des Landes dar, da sie für jeden Impfstoff bezahlt werden und mehr Fußgängerverkehr in die Geschäfte bringen. Der Impfstoff-Rollout wird auch das Engagement der Unternehmen für die Ausweitung des Zugangs zur Gesundheitsversorgung in schwarzen und hispanischen Gemeinden testen.

Banks, ein Arzt für Infektionskrankheiten in Ohio, ist Teil einer Interessengruppe der Infectious Diseases Society of America, die sich aus schwarzen Ärzten, Wissenschaftlern und Beamten des öffentlichen Gesundheitswesens zusammensetzt, die sich mit der Beseitigung von Disparitäten im Gesundheitswesen befassen. Sie sagte, dass Gesundheitsdienstleister kreativ werden und Engagement zeigen müssen. Sie sagte, sie sollten Kliniken an vertrauten Orten wie Kirchen einrichten und “vertrauenswürdige Boten” wie Pastoren und Gemeindevorsteher gewinnen.

“Man muss sich aus kultureller Sicht ansehen, wo wir sind.” und komm zu uns “, sagte sie.

Mehr als Fairness

Die Einführung des Impfstoffs in den USA war langsam und komplex. Die Nachfrage nach Dosen hat die Anzahl der Schüsse, die zum Einstechen in die Arme zur Verfügung stehen, bei weitem überwogen. Online-Terminsysteme waren schwierig zu navigieren und wurden von starkem Verkehr blockiert. Bisher haben nur zwei Impfstoffe eine Notfallgenehmigung der Food and Drug Administration und müssen bei kalten und ultrakalten Temperaturen gelagert werden. Und nur einige Amerikaner qualifizieren sich für den Schuss, wobei jeder Staat leicht unterschiedliche Kriterien hat, um Faktoren wie Alter, Gesundheitszustand oder Arbeit einer Person abzuwägen.

Laut den Centers for Disease Control and Prevention wurden in den USA bis Freitag etwa 48,4 Millionen Impfstoffe verabreicht. Fast 12,1 Millionen Menschen haben beide Dosen des Impfstoffs erhalten – nur ein kleiner Teil der 331 Millionen Menschen, die in den USA leben

Das Ziel des Landes ist es, zwischen 70% und 85% der US-Bevölkerung – oder etwa 232 bis 281 Millionen Menschen – zu impfen, um eine Herdenimmunität zu erreichen, so Dr. Anthony Fauci, der Chefarzt des Präsidenten.

Personen ohne Termin stehen an, um möglicherweise eine Dosis des Pfizer-BioNTech Covid-19-Impfstoffs zu erhalten, nachdem alle Termine am Donnerstag, dem 11. Februar 2021, an der Impfstelle des Sun City Anthem Community Center in Henderson, Nevada, verabreicht wurden.

Roger Kisby | Bloomberg | Getty Images

Der chaotische Rollout hat dazu geführt, dass einige Aufnahmen gemacht haben und andere nicht. Laut einer CDC-Studie waren die meisten der fast 13 Millionen Menschen, denen innerhalb des ersten Monats nach der Verteilung der Medikamente mindestens ein Schuss eines Covid-19-Impfstoffs verabreicht wurde, Frauen im Alter von 50 Jahren oder älter und wahrscheinlich nicht spanisch und weiß.

Bei der Verteilung von Impfstoffen ist Gerechtigkeit nicht nur eine Frage der Fairness. Dies ist auch ein entscheidender Weg, um die Ausbreitung in Gemeinden zu verlangsamen, in denen Covid-19-Fälle, Krankenhausaufenthalte und Todesfälle häufiger auftreten. Schwarze und hispanische Amerikaner werden nach Angaben der CDC Ende November 3,7-mal und 4,1-mal häufiger aus Covid ins Krankenhaus eingeliefert als weiße Amerikaner. Beide Minderheiten sterben 2,8-mal häufiger an der Krankheit als weiße Amerikaner.

In einem stark betroffenen Viertel kann die Wirkung jedes Schusses noch größer sein – Menschen erreichen, die einem höheren Risiko ausgesetzt sind, wenn sie in Lebensmittelgeschäften oder an anderen Arbeitsplätzen an vorderster Front arbeiten oder in einer dichten Wohnung oder in Haushalten mit mehreren Generationen leben.

Das Zögern bei Impfungen ist auch bei Schwarzen und Braunen höher, was auf die Geschichte der medizinischen Gemeinschaft zurückzuführen ist, in der Minderheiten misshandelt und weniger Gesundheitspraktiken in ihrer Nachbarschaft eröffnet wurden. Eine von der Association for a Better New York durchgeführte Umfrage unter New Yorkern ergab, dass 78% der Einwohner von White den Impfstoff so schnell wie möglich einnehmen würden, verglichen mit 39% der Einwohner von Black, 54% der Hispanics und 54% der Asiaten .

“Setzen Sie ihr Geld, wo ihr Mund ist”

Für Anbieter wie CVS und Walgreens ist es eine Geschäftsmöglichkeit, mehr Dosen des Impfstoffs zu haben. Sie werden für jeden Impfstoff bezahlt und die Regierung übernimmt die Kosten, wenn eine Person nicht krankenversichert ist. Jefferies schätzte, dass jeder Schuss eine Bruttomarge von 13 bis 15 US-Dollar haben wird und im nächsten Jahr einen zusätzlichen Bruttogewinn von etwa 1 Milliarde US-Dollar für CVS bringen könnte.

Beide Drogerieketten haben ihre Strategie festgelegt, mehr Gesundheitsdienstleistungen von Kliniken für Grundversorgung zu Diabetes-Screenings hinzuzufügen. Sie haben auch ihre Verpflichtungen zur Beseitigung von Rassenungleichheiten als Reaktion auf George Floyds Mord und landesweite Proteste verstärkt. CVS plant, über einen Zeitraum von fünf Jahren fast 600 Millionen US-Dollar zu investieren, um politische Initiativen und interne Bemühungen zu unterstützen, z. B. die Betreuung schwarzer Mitarbeiter und kostenlose Gesundheitsuntersuchungen auf Blutdruck und Cholesterin in Geschäften.

Walgreens startete ein Pilotprojekt in der Region Chicago, das darauf abzielt, die Krankenhausaufenthaltsraten zu senken, indem es Patienten erleichtert wird, ihre Medikamente einzunehmen, kostenlose Verschreibungen zu erhalten und regelmäßiger mit Angehörigen der Gesundheitsberufe über ihren Gesundheitszustand in Kontakt zu treten. Das Unternehmen hat kürzlich den ehemaligen Chief Operating Officer von Starbucks, Roz Brewer, als nächsten CEO eingestellt. Wenn sie Mitte März in die Rolle eintritt, wird sie nur eine schwarze Frau sein, die ein Fortune 500-Unternehmen leitet.

Karyne Jones, Der CEO des National Caucus and Center on Black Aging in Washington, DC, sagte, die Ausweitung von Impfstoffen auf schwer betroffene Gemeinden sei eine Möglichkeit für CVS und Walgreens, “ihr Geld dort einzusetzen, wo ihr Mund ist”. Ihre Organisation ist Gründungsmitglied des Covid-19 Vaccine Education and Equity Project, einer Koalition von gemeinnützigen Organisationen und Handelsgruppen, die vom Impfstoffhersteller Pfizer unterstützt wird.

Jones sagte, sie würde gerne sehen, wie CVS und Walgreens rund um die Uhr Impfstellen öffnen und Zelte in Gegenden aufbauen, in denen die Menschen keinen Transport haben.

“Wenn Sie wirklich gute unternehmerische Verantwortung zeigen wollen, ist dies die Zeit zu sagen, dass wir Ressourcen einsetzen müssen, um diese Pandemie zu lindern”, sagte sie.

Wir haben Apothekenwüsten. Wir haben Wüsten für Lebensmittelgeschäfte. Wir haben keine kirchlichen Wüsten.

Dr. Virginia Banks

Spezialist für Infektionskrankheiten

Banks, der Arzt für Infektionskrankheiten, sagte, er werde über den Tellerrand hinaus Strategien verfolgen, wie beispielsweise die Umleitung von Buslinien zu Impfkliniken. Sie wies auf eine Anstrengung hin, bei der sich Apotheker mit Friseurläden zusammengetan hatten, um Bluthochdruck zu erkennen, als schwarze Männer einen Haarschnitt machten – eine klinische Studie, die half, den Zustand zu erkennen und früher einzugreifen.

Sie sagte, sie hoffe, dass der Johnson & Johnson-Impfstoff – der nur eine Dosis benötigt und leichter transportiert werden kann – die Verteilung verändern und es einfacher machen könnte, Schüsse dort abzugeben, wo sich Menschen befinden. Das Unternehmen hat letzte Woche bei der FDA eine Genehmigung für den Notfall beantragt.

“Wir haben Apothekenwüsten”, sagte sie. “Wir haben Wüsten für Lebensmittelgeschäfte. Wir haben keine Wüsten für Kirchen.”

Dosen in mehr Stadtteilen

Walgreens und CVS haben in Tausenden von Pflegeheimen und Einrichtungen für betreutes Wohnen Covid-Impfstoffe verabreicht. Sie haben in einigen Geschäften Schüsse verabreicht, nachdem sie Impfstoffdosen von Staaten erhalten hatten. Mit dem Bundesprogramm werden sie Aufnahmen in mehr Stadtteilen anbieten.

Walgreens hat Covid-Impfstoffe in Geschäften in 15 Bundesstaaten und zwei weiteren Gerichtsbarkeiten, New York City und Chicago. Im Rahmen des Bundesprogramms werden Aufnahmen in 1.800 Filialen gemacht – oder rund 20% der US-Filialen, sagte eine Unternehmenssprecherin.

CVS hat sie in 18 Staaten und Puerto Rico. Ab Freitag werden rund 420 der rund 9.900 Filialen die Aufnahmen mit Dosen eines staatlichen oder föderalen Programms machen, sagte ein Unternehmenssprecher.

Beide Apothekenketten gaben an, Geschäfte in Gegenden mit größerem Bedarf ausgewählt zu haben. Etwa die Hälfte der Geschäfte jedes Unternehmens mit Covid-Impfstoffen befindet sich in medizinisch unterversorgten Gebieten oder an Orten, die auf dem CDC-Index für soziale Anfälligkeit einen hohen Stellenwert haben. Dieser basiert auf Faktoren wie der Verbreitung von Armut, mangelndem Zugang zu Fahrzeugen und überfüllten Wohnungen.

Mit Walgreens können Personen auch Termine persönlich oder telefonisch vereinbaren, sodass Personen nicht ausgeschlossen werden, wenn sie kein Internet oder keinen Computer haben, sagte Rina Shah, Vizepräsidentin der Walgreens-Gruppe für Apothekenbetriebe. CVS hat eine 1-800-Nummer als Alternative zur Online-Buchung.

Walgreens ging eine Partnerschaft mit Uber ein, um Menschen, die in unterversorgten Teilen von Großstädten wie Atlanta und Chicago leben, kostenlose Fahrten zu Impfungen zu ermöglichen. Wohltätige Partner helfen bei der Identifizierung von Personen, die Transport benötigen.

CVS unternimmt proaktive Schritte, um sicherzustellen, dass die Einheimischen Impfstofftermine in ihrem nahe gelegenen Geschäft erhalten können, sagte Chris Cox, Senior Vice President für Pharmazie des Unternehmens. Er sagte, dass Mitarbeiter einige Kunden anrufen, um ihre Termine zu vereinbaren, insbesondere diejenigen, die ein niedrigeres Einkommen haben und älter sind.

Zusammen mit der Anwerbung von Apotheken wird die Biden-Regierung nächste Woche Dosen an kommunale Gesundheitszentren liefern, die Millionen von Amerikanern dienen, die unterhalb der Armutsgrenze leben und rassische Minderheiten sind.

Das Impfprogramm ermöglicht es CVS, eindringlich zu demonstrieren, wie es Gesundheitsversorgung an Orten anbieten kann, an denen es normalerweise nicht zugänglich ist, sagte Cox.

“Alles, was wir tun, ist wirklich mit der Absicht, Menschen auf ihrem Weg zu einer besseren Gesundheit zu helfen”, sagte er. “Diese Gelegenheit bietet uns wirklich, unseren Patienten und anderen Interessengruppen zu demonstrieren, was wir seit mehreren Jahren sagen. Das heißt, dass die Gemeinschaftsapotheke eine große Rolle im Gesundheitswesen spielt.”

Viele Patienten sehen ihre Apotheker häufiger als ihre Ärzte, da sie Bluthochdruckpillen oder andere Erhaltungsrezepte abholen müssen, sagte er. Diese häufigen Wechselwirkungen bedeuten, dass CVS eine größere Rolle dabei spielen kann, sicherzustellen, dass Menschen ihre Medikamente richtig einnehmen, oder vor möglichen Komplikationen eingreifen kann.

Da Walgreens mehr Angebot erhält, wird Shah seine Arbeitszeiten verlängern und an Wochenenden Aufnahmen für Leute anbieten, die keinen Arbeitstag auslassen können. Es wird Kliniken in Gemeindezentren eröffnen, wie es bei Grippeschutzimpfungen der Fall ist.

Shah sagte, dass seine Apotheker eine Schlüsselrolle bei der Aufklärung und Beantwortung von Fragen spielen können, so dass die Leute eher auf die Aufnahmen gespannt sind als besorgt. Aber sie sagte, das Unternehmen brauche letztendlich mehr Versorgung, um mehr Menschen in Minderheitengemeinschaften zu erreichen.

“Unsere größte Chance ist es, mehr Impfstoffe zu bekommen”, sagte sie.

Categories
Health

Major Care Docs Really feel Left Out of Vaccine Rollout

Primary Care Doctors Feel Left Out of Vaccine Rollout

Despite their willingness to participate, only one in five GPs said they gave their patients the vaccine. This was found in a survey conducted in mid-January by the Larry A. Green Center with the nonprofit Primary Care Collaborative. Given the widespread supply shortages, many were unable to get the vaccine and a third of them said they had not had contact with their local health department.

Dr. Katelin Haley, a family doctor in Lewes, Delaware, is one of the lucky few who just received 240 doses of the vaccine and will immunize patients this week. Your employees had asked the state every day when they could expect a delivery. “The hunt for the vaccine was almost a full-time occupation,” she said.

While Dr. Haley, who also works with Aledade, agrees with the state’s struggle for adequate supplies of the vaccine, she believes practices like hers need some of the doses. “It’s a delicate balance to meet the needs of the state and the needs of the individual practice,” she said.

Some doctors, like Dr. Altman, have received small amounts of the vaccine but do not know when they may have enough to immunize all qualified patients. At the end of January, Dr. Despite the cold weather, Altman and his staff vaccinated 200 patients in the practice parking lot. “The patients were literally in tears, they were so grateful for our efforts,” he said.

The Trump administration left it up to states to determine how to distribute the vaccines, and states and even local communities are taking different approaches. “So much of whether primary care is used effectively depends on the state,” said Ann Greiner, executive director of the Primary Care Collaborative.

Although demand for vaccines is currently outstripping supply, it is important to rely on family doctors to vaccinate the public when supply exceeds demand later in the year, said Dr. Asaf Bitton, a family doctor who is the general manager of Ariadne Labs, is at Brigham and Women’s Hospital and the Harvard TH Chan School of Public Health. Your involvement will be crucial in overcoming vaccine hesitation and achieving herd immunity.

As some conversations begin, “they should have started six months ago,” he said.

Categories
Health

AstraZeneca races to adapt Covid vaccine as South Africa halts rollout

AstraZeneca races to adapt Covid vaccine as South Africa halts rollout

The dose of Oxford University / AstraZeneca COVID-19 vaccine will be displayed from its box on January 2nd, 2021 at the Princess Royal Hospital, Haywards Heath, West Sussex, UK.

Gareth Fuller | Reuters

Drug maker AstraZeneca is making efforts to adapt its Covid-19 vaccine in light of new variants of the virus. The process is becoming more urgent after a small study found it less effective at protecting against the more virulent strain discovered in South Africa.

The country said it will end the use of the shot in its vaccination program after a study published on Sunday that has not yet been peer-reviewed found the vaccine offered “minimal protection” against mild to moderate illnesses caused by the South African variant will.

Researchers from the University of Witwatersrand and others in South Africa, as well as the University of Oxford, found the study was small, with only about 2,000 volunteers, with a mean age of 31. Oxford University said: “Protection from moderate to severe illness, hospitalization or death could not be assessed in this study because the target group was exposed to such a low risk.”

The vaccine manufacturers had already started developing second-generation Covid vaccines, which will target new variants of the virus. Experts say it shouldn’t be too difficult to tweak existing vaccines to cover mutations, and that they could be adjusted within six weeks.

Sarah Gilbert, professor of vaccinology at Oxford University who developed the vaccine with AstraZeneca, said Sunday that “efforts are being made to develop a new generation of vaccines that will allow protection on new variants as booster jabs redirect if this is the case. ” it turns out that it is necessary to do so. “

“We are working with AstraZeneca to optimize the pipeline that would be required for a strain change should one become necessary. This is the same problem all vaccine developers face and we will continue to monitor the emergence of new variants that arise in the readiness for a future change of burden.

The variant, officially known as the B.1.351 mutation, was first detected in South Africa in October 2020 and has since become dominant in the country.

Several cases have also been found elsewhere of health officials making efforts to stop the spread of the mutation, which has been found to be more contagious. There were already concerns that this variant might be more resistant to coronavirus vaccines developed last year.

With the use of the AstraZeneca-Oxford University jab stopped, the South African government will instead offer vaccines made by Johnson & Johnson and Pfizer.

In late January, Johnson & Johnson reported that its single-dose shot was 57% effective in one of its clinical trials in South Africa, where almost all Covid-19 cases (95%) were due to variant B infection. 1,351 descent. For comparison, the vaccine was found to be 72% effective in the US arm of the study.

Pfizer-BioNTech and Moderna have both reported early signs that their vaccinations offer protection against new known variants of the virus found in South Africa and the UK

On Friday, Oxford University released details of a separate study showing the vaccine was effective against a variant of the virus that was first discovered in south-east England and has now become the dominant strain in the UK

Andrew Pollard, professor of pediatric infection and immunity and lead investigator of the Oxford vaccine study, said data from studies of its vaccine in the UK “shows that the vaccine protects not only against the original pandemic virus, but also against the novel variant B.1.1 .7, which caused the rise in disease across the UK from late 2020. “

Categories
World News

Vaccine Rollout Provides U.Okay. a Uncommon Win within the Pandemic

Vaccine Rollout Gives U.K. a Rare Win in the Pandemic

“With the UK, we had an additional three months to fix any issues we encountered,” AstraZeneca CEO Pascal Soriot told an Italian newspaper, la Repubblica, this week.

On Friday, the European Union drug regulators approved the AstraZeneca vaccine for all adults, following the precedent set by the UK regulator last month.

Britain could get another vaccine soon.

Novavax, a biotechnology company based in Gaithersburg, Md., Reported Friday that its vaccine was 89.3 percent effective in a large-scale study in the UK. The government has secured 60 million cans made at a facility in north east England. If the UK regulators approve, the vaccine will be dispensed in the second half of 2021.

In total, the UK government has spent at least £ 11.7 billion, or $ 16 billion, developing, manufacturing, buying and administering vaccines.

“The vaccination is the only thing we got right,” said Christina Pagel, professor of operational research at University College London.

That doesn’t mean that the rollout was free of tension. With hospital congestion and a contagious variant across the country, the UK has bet on giving more people partial protection from a single dose rather than quickly giving fewer people full protection from two doses.

Doctors whose booster vaccinations were delayed were upset with the approach, accusing the government of making them the subject of a risky new experiment that they fear will make vaccines less effective. Immunologists have raised concerns that a country full of people with only partial immunity could produce vaccine-resistant mutations, while Pfizer said the strategy is not supported by the data gathered in clinical trials.